Written by Jackie Howard
Wednesday, 28 April 2010 12:46
Sir Colin Dollery graduated from Birmingham University with honours degrees in physiology and in medicine. He spent almost all his academic career at the Royal Postgraduate Medical School at Hammersmith Hospital and established one of the world-leading departments of clinical pharmacology. His clinical interest was particularly in the treatment of hypertension both in early phase studies and in the large scale clinical trials conducted by the MRC. Later in his career he was successively Chairman of the Department of Medicine and Dean of the Medical School. He had a prominent national and international role in clinical pharmacology and pharmacology and was the first (and so far the only) clinical pharmacologist to become President of the International Union of Pharmacology (IUPHAR). Graduates from his department filled many of the professorial chairs of clinical pharmacology in UK and overseas universities. He was the managing Editor of the two volume reference book, “Therapeutic Drugs”. He is still a member of the receptor nomenclature committee of IUPHAR (NC-IUPHAR). He served on many public committees in the UK including the Committee on Safety of Medicines, Medical Sub-Committee of the University Grants Committee (Chairman) and the Physiological Systems Board (Chairman) of the Medical Research Council and served 20 years on the Hong Kong University Grants Committee. He was Pro-Vice-Chancellor for Medicine of the University of London during the period when there was government pressure to close a number of the strongest research based teaching hospitals in London and was successful in co-ordinating efforts to convince the government otherwise.
Since his retirement from the University of London in 1996 Sir Colin has been a senior consultant to the head of Research and Development in GlaxoSmithKline, Dr Moncef Slaoui, and before that in SmithKline Beecham, for 14 years. This is virtually a full time position. He is particularly concerned with the discovery-development interface when new drugs transfer from the laboratory to early studies in man. He serves on the committee that reviews protocols for early phases of research in man with new medicines, the Global Safety Board that reviews all issues related to safety, including approval for first administration of a new drug to man and the Pharmaceutical Management Board that makes the major investment decisions about the later phases of drug development.
He was co-Chairman of the ABPI/BIA Working Party on the Tegenero 1412 episode at Parexel, Northwick Park. More recently he co-chaired a joint working party of the Academy of Medical Sciences and the Royal Academy of Engineering on Systems Biology and a working party of the Academy of Medical Sciences that produced a report on Safer Medicines.
In 2008 he was awarded the Wellcome Gold Medal of the British Pharmacological Society for his work in clinical pharmacology and in 2009 the Oscar B Hunter award in therapeutics of the American Society of Clinical Pharmacology and Therapeutics.
1. C.T. Dollery (main author of final text) Safer Medicines, Academy of Medical Sciences 2005.
2. C.T. Dollery. Clinical Pharmacology the first 75 years and a view of the future. British Journal of Clinical Pharmacology 61(6):650-665, 2006
3. C.T. Dollery (Co-Chairman). Early Stage Clinical Trial Taskforce, Joint ABPI/BIA Report. 2006.
4. C.T. Dollery (Co-Chairman). Systems Biology: a vision for engineering and medicine. Academy of Medical Sciences and Royal Academy of Engineering. 2007.
5. C.T. Dollery. Beyond Genomics. Clin Pharm & Ther 82(4):366-369, 2007.
6. C.T Dollery. Clinical Pharmacology in the Molecular Era, Clin Pharm & Ther 83: 220-225, 2008
7. C.T Dollery. The Scientific Contribution of Clinical Pharmacology. European Journal of Clinical Pharmacology 64: 99-106, 2008